Completed PHASE2 INTERVENTIONAL 1-arm NCT03155425

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Classic Hodgkin's Lymphoma

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Hodgkin Lymphoma, Adult

Interventions SHR-1210

Updated 10 times since 2017 Last updated: Jan 31, 2024 Started: Jun 9, 2017 Primary completion: Aug 31, 2020 Completion: Sep 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hodgkin Lymphoma, Adult, this trial is completed. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 10 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2024 — Jul 2024 [monthly]

Completed PHASE2
Apr 2023 — Mar 2024 [monthly]

Completed PHASE2
Dec 2021 — Apr 2023 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 5 earlier versions

Jan 2021 — Dec 2021 [monthly]

Unknown Status PHASE2
Feb 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Feb 2020 [monthly]

Recruiting PHASE2
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2017 — Dec 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China
• Nanjing, China